Given the agenda’s unique focus on the impact of healthcare reform on the role of medical affairs - and specifically medical science liaison activities with internal and external stakeholders - we expect 100+ medical affairs and MSL professionals from pharmaceutical, biotech, device, and diagnostic companies to be in attendance, including the following professionals:

• Medical Affairs (VPs, Directors, Managers)
• Medical Science Liaison Team Leaders
• Medical Science Liaisons (All Levels)
• Managed Care Liaisons
• Health Outcome Liaisons
• Medical Directors
• Scientific Liaisons
• Scientific Affairs
• Thought Leader Liaisons
• KOL/Liaison Management
• Clinical Trial Liaisons
• Clinical Affairs
• Clinical / Outcome Liaisons
• Therapeutic Leads